Enoxaparin in Treatment of Vascular Intra-Uterine Growth Retardation

Evaluation of Efficacy and Safety of Enoxaparin in Treatment of Vascular Intra-Uterine Growth Retardation: A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180819040830N4

Enrollment

126

Registered

2020-05-01

Start date

2019-12-26

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-uterine growth retardation.

Interventions

Intervention 1: Intervention group: 4000 IU per day SC enoxaparin. Intervention 2: Control group: routine care.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: >18 years old women with singleton pregnant women Diagnosis of intra-uterine growth retardation for their fetus

Exclusion criteria

Exclusion criteria: Maternal age <18 years old Multiple pregnanvy

Design outcomes

Primary

Measure	Time frame
Birth weight. Timepoint: At delivery time. Method of measurement: Measuring neonatal birth weight by an electronic scale.	—

Secondary

Measure	Time frame
Enoxaparin side effects (including active bleeding due to enoxaparine use or thrombocytopena after beginning the enoxaparin. Timepoint: Any time after beginning the study. Method of measurement: History taking, physical exam, laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Naeiji

Shahid Beheshti University of Medical Sciences

zahranaeiji98@yahoo.com+98 21 5506 2628

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026